
    
      The purpose of the escalation part of the trial is to determine the maximum tolerated dose
      (MTD) and the recommended phase 2 dose (RP2D), as well as to establish the safety profile of
      GEN3014 (HexaBodyÂ®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic
      Malignancies
    
  